查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1968517

PD-1抗藥性頭頸癌市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、最終用戶、地區和競爭對手分類，2021-2031年

PD-1 Resistant Head and Neck Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球 PD-1 抗藥性頭頸癌市場預計將從 2025 年的 13.1 億美元成長到 2031 年的 22.5 億美元，複合年成長率為 9.43%。

此領域的治療方法包括針對接受免疫查核點抑制劑治療後病情進展的鱗狀細胞癌患者的二線治療通訊協定。市場成長的主要促進因素是原發性普遍，這使得轉移性或復發性疾病患者迫切需要有效的挽救性治療。此外，全球頭頸部惡性腫瘤發生率的上升，以及基於生物標記的患者篩選方法的普及，也持續推動著對能夠延長這一高風險患者群體生存期的替代治療方法的需求。

市場概覽
預測期 2027-2031
市場規模：2025年 13.1億美元
市場規模：2031年 22.5億美元
複合年成長率：2026-2031年 9.43%
成長最快的細分市場 醫院
最大的市場 北美洲

複雜的腫瘤微環境為市場成長帶來了巨大挑戰。這種環境常會抑制研發階段藥物的療效，導致臨床試驗失敗率居高不下。根據美國臨床腫瘤學會（ASCO）預測，到2025年，臨床數據顯示，只有約15%至20%的複發性頭頸癌患者能夠對免疫查核點抑制劑產生持續反應。這項數據表明，開發能夠有效克服免疫逃脫機制並提高患者存活率的二線治療方法是一項極其艱鉅的任務。

市場促進因素

該市場的主要促進因素是，儘管接受了查核點抑制劑治療，但仍有相當一部分患者對標準治療無效。隨著免疫療法在早期治療方案中的應用，儘管PD-1抑制劑的使用增加，但患者病情仍持續進展，導致治療缺口顯著擴大。這一問題的規模十分巨大。默克在2025年2月報告稱，Keytruda在2024年的全球銷售額達到295億美元，這一數字表明，大量患者可能面臨獲得性抗藥性的風險。 Keytruda的廣泛使用直接導致需要挽救性治療的難治性病例增加。此外，美國癌症研究協會在2024年1月預測，當年美國將新增超過7萬例頭頸癌病例，這意味著將有源源不絕的患者最終需要接受抗藥性治療。

同時，新一代抗體藥物偶聯物（ADC）和雙特異性抗體的興起，透過提供克服免疫抑制的新機制，正在改變治療模式。與傳統治療方法不同，這些先進治療方法透過精準標靶化抗原或活化替代免疫效應細胞，有效繞過功能異常的PD-1通路，遞送細胞毒性有效載荷。這些藥物的臨床潛力正日益凸顯。 2024年12月，Merus NV公司發布了更新的試驗數據，顯示雙特異性抗體petosemtamab在復發或轉移性頭頸部鱗狀細胞癌患者中獲得了40.4%的確認總緩解率。這項療效顯著優於傳統挽救療法的成功率，促使研發投入迅速成長，並作為強效的難治性患者替代療法，吸引了業界的廣泛關注。

市場挑戰

全球PD-1抗藥性頭頸癌市場面臨的主要障礙之一是複雜的腫瘤微環境。這種生物學複雜性常常使在研藥物的作用機制失效，進而在研發階段造成巨大的療效挑戰。如果新化合物無法有效滲透或調節腫瘤微環境，就會導致臨床試驗的高脫落率。此類失敗會擾亂商業化進程，造成監管核准的顯著延遲，並加重那些在最終失敗的候選藥物上投入巨資的製藥公司的財務負擔。

持續無法克服這些生物學屏障與不良的臨床結果和挽救性治療市場進展緩慢直接相關。治療限制的影響體現在患者死亡率上，凸顯了有效二線治療方案的匱乏。根據美國癌症協會統計，2024年美國約有12,690人死於口腔癌和咽癌。如此高的死亡率凸顯了抗藥性機制對市場的影響，並表明持續缺乏能夠證明可克服腫瘤微環境的藥物有效性的證據，限制了盈利產品的市場准入。

市場趨勢

個人化新抗原和人類乳突病毒(HPV)疫苗的研發正在改變市場格局，其關注點也從廣譜查核點抑制轉向精準的抗原特異性T細胞活化。這一趨勢旨在滿足HPV相關惡性腫瘤患者的關鍵未滿足需求，這些患者由於抗原流失和T細胞耗竭而容易對標準免疫療法產生抗藥性。研發人員正在利用基於胜肽的策略和融合蛋白來重新運作難治性病例的免疫系統。新型生物製藥CUE-101已證實了此方法的有效性。據Cue Biopharma公司（2024年6月公佈）稱，在一項I期劑量遞增研究中，CUE-101單藥治療使復發/轉移性HPV16陽性頭頸癌患者的中位總生存期達到20.8個月，顯著超過了此前約8個月的基準值。

同時，人工智慧驅動的新標靶發現和抗藥性分析正在加速識別參與腫瘤生長的隱性新抗原。傳統技術往往無法檢測到免疫抑制性腫瘤微環境中的稀疏或複雜突變，導致治療失敗。人工智慧驅動的平台克服了這一局限性，能夠以極高的準確度預測高親和性新抗原，從而加速開發完全個人化的療法。 2024年11月，NEC公司在一份題為「Transgene和NEC公佈新數據」的新聞稿中強調了這一能力，該新聞稿宣布，經人工智慧最佳化的新抗原疫苗「TG4050」在接受輔助性治療的頭頸癌患者中實現了100%的無病生存率。這充分展現了電腦輔助發現克服抗藥性機制的強大能力。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：PD-1抗藥性頭頸癌的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 副產物（細胞毒性藥物、EGFR抑制劑、PD-1抑制劑、在研藥物）
    • 依最終用戶（醫院、診所等）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美PD-1抗藥性頭頸癌市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲PD-1抗藥性頭頸癌市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區PD-1抗藥性頭頸癌市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲PD-1抗藥性頭頸癌市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲PD-1抗藥性頭頸癌市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球PD-1抗藥性頭頸癌市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Ayala Pharmaceuticals D srl.
  • Amgen Inc.
  • AstraZeneca plc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cel-Sci
  • GSK plc
  • Incyte
  • Merck KGaA
  • Novartis AG

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 20202

The Global PD-1 Resistant Head and Neck Cancer Market is projected to expand from USD 1.31 Billion in 2025 to USD 2.25 Billion by 2031, registering a CAGR of 9.43%. Therapies in this sector involve secondary treatment protocols designed for patients with squamous cell carcinoma who exhibit disease progression following immune checkpoint inhibitor administration. Growth in this market is primarily fueled by the prevalence of both primary and acquired resistance to standard care agents, creating an urgent need for effective salvage therapies for metastatic or recurrent conditions. Additionally, the increasing global incidence of head and neck malignancies, combined with the adoption of biomarker-based patient selection, reinforces the sustained demand for alternative treatments capable of extending survival in this challenging patient group.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.31 Billion
Market Size 2031USD 2.25 Billion
CAGR 2026-20319.43%
Fastest Growing SegmentHospitals
Largest MarketNorth America

Market growth encounters significant hurdles due to the complex tumor microenvironment, which frequently hampers the effectiveness of investigational drugs and results in high failure rates during clinical trials. According to the American Society of Clinical Oncology, clinical data in 2025 indicates that durable responses to immune checkpoint inhibitors are achieved in only approximately 15% to 20% of patients with recurrent head and neck cancer. This statistic underscores the substantial challenge in developing successful second-line regimens that can effectively overcome immune evasion mechanisms and enhance patient survival outcomes.

Market Driver

The primary catalyst driving this market is the expanding population of patients who have been exposed to checkpoint inhibitors yet fail to respond to standard of care. As immunotherapy is increasingly adopted in earlier lines of treatment, a larger cohort is experiencing disease progression despite PD-1 blockade, resulting in a critical treatment gap. The magnitude of this issue is substantial; Merck & Co. reported in February 2025 that full-year 2024 global sales of Keytruda hit $29.5 billion, a figure that highlights the vast number of patients susceptible to potential acquired resistance. This widespread usage directly links to an increasing volume of refractory cases needing salvage therapy. Moreover, the American Cancer Society projected in January 2024 that over 70,000 new head and neck cancer cases would be diagnosed in the United States that year, maintaining a steady pipeline of patients who may eventually require interventions for resistant disease.

Concurrently, the rise of next-generation antibody-drug conjugates and bispecific antibodies is transforming the therapeutic landscape by providing new mechanisms to surmount immunosuppression. In contrast to traditional therapies, these advanced modalities employ precise antigen targeting to deploy cytotoxic payloads or activate alternative immune effectors, effectively bypassing compromised PD-1 pathways. The clinical potential of these agents is increasingly apparent; in December 2024, Merus N.V. released updated trial data showing that the bispecific antibody petosemtamab attained a confirmed overall response rate of 40.4% in patients with recurrent or metastatic head and neck squamous cell carcinoma. This level of efficacy significantly exceeds historical salvage rates, spurring rapid R&D investment and redirecting industry focus toward these potent alternatives for the refractory population.

Market Challenge

A major obstacle hindering the Global PD-1 Resistant Head and Neck Cancer Market is the complex tumor microenvironment. This biological intricacy often neutralizes the mechanisms of action in investigational drugs, causing substantial efficacy challenges during the developmental phase. When new compounds fail to effectively penetrate or modulate the tumor environment, it leads to high attrition rates in clinical trials. Such failures disrupt the commercial pipeline by causing significant delays in regulatory approvals and increasing financial strain on pharmaceutical developers who invest heavily in candidates that ultimately do not succeed.

The continued inability to overcome these biological barriers correlates directly with poor clinical outcomes and a lack of progress in the salvage therapy market. The impact of these therapeutic limitations is reflected in patient mortality rates, emphasizing the scarcity of effective second-line options. According to the American Cancer Society, approximately 12,690 deaths in the United States were attributed to oral cavity and pharynx cancers in 2024. This high mortality figure highlights the market consequences of resistance mechanisms, as the persistent failure to validate agents capable of conquering the microenvironment limits the launch of revenue-generating products.

Market Trends

The market is being transformed by the development of personalized neoantigen and HPV vaccines, shifting focus from broad checkpoint blockade to precise antigen-specific T-cell engagement. This trend targets a critical unmet need in patients with HPV-driven malignancies, who often develop resistance to standard immunotherapies due to antigen loss or T-cell exhaustion. Developers are utilizing peptide-based strategies and fusion proteins to successfully reactivate the immune system in refractory cases. The efficacy of this approach was demonstrated by the novel biologic CUE-101; according to Cue Biopharma in June 2024, the 'Phase 1 dose-escalation and expansion study' showed that CUE-101 monotherapy achieved a median overall survival of 20.8 months in patients with recurrent/metastatic HPV16+ head and neck cancer, significantly surpassing the historical benchmark of roughly eight months.

Simultaneously, the use of AI in novel target discovery and resistance profiling is expediting the identification of cryptic neoantigens responsible for tumor progression. Traditional techniques often struggle to detect sparse or complex mutations within the immunosuppressive tumor microenvironment, resulting in therapeutic failure. AI-driven platforms overcome this limitation by predicting high-affinity neoantigens with exceptional accuracy, facilitating the development of fully personalized treatments. This capability was emphasized in November 2024, when NEC Corporation reported in the 'Transgene and NEC Present New Data' release that the AI-optimized neoantigen vaccine TG4050 achieved a 100% disease-free survival rate in adjuvant head and neck cancer patients, validating the power of computational discovery in surmounting resistance mechanisms.

Key Market Players

  • Ayala Pharmaceuticals D srl.
  • Amgen Inc.
  • AstraZeneca plc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cel-Sci
  • GSK plc
  • Incyte
  • Merck KGaA
  • Novartis AG

Report Scope

In this report, the Global PD-1 Resistant Head and Neck Cancer Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

PD-1 Resistant Head and Neck Cancer Market, By Product

  • Cytotoxic Agents
  • EGFR Inhibitors
  • PD-1 Inhibitors
  • Pipeline Drugs

PD-1 Resistant Head and Neck Cancer Market, By End User

  • Hospitals
  • Clinics
  • Others

PD-1 Resistant Head and Neck Cancer Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global PD-1 Resistant Head and Neck Cancer Market.

Available Customizations:

Global PD-1 Resistant Head and Neck Cancer Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global PD-1 Resistant Head and Neck Cancer Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Cytotoxic Agents, EGFR Inhibitors, PD-1 Inhibitors, Pipeline Drugs)
    • 5.2.2. By End User (Hospitals, Clinics, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America PD-1 Resistant Head and Neck Cancer Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States PD-1 Resistant Head and Neck Cancer Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada PD-1 Resistant Head and Neck Cancer Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico PD-1 Resistant Head and Neck Cancer Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By End User

7. Europe PD-1 Resistant Head and Neck Cancer Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany PD-1 Resistant Head and Neck Cancer Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By End User
    • 7.3.2. France PD-1 Resistant Head and Neck Cancer Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom PD-1 Resistant Head and Neck Cancer Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy PD-1 Resistant Head and Neck Cancer Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain PD-1 Resistant Head and Neck Cancer Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By End User

8. Asia Pacific PD-1 Resistant Head and Neck Cancer Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China PD-1 Resistant Head and Neck Cancer Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By End User
    • 8.3.2. India PD-1 Resistant Head and Neck Cancer Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan PD-1 Resistant Head and Neck Cancer Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea PD-1 Resistant Head and Neck Cancer Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia PD-1 Resistant Head and Neck Cancer Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By End User

9. Middle East & Africa PD-1 Resistant Head and Neck Cancer Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia PD-1 Resistant Head and Neck Cancer Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By End User
    • 9.3.2. UAE PD-1 Resistant Head and Neck Cancer Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By End User
    • 9.3.3. South Africa PD-1 Resistant Head and Neck Cancer Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By End User

10. South America PD-1 Resistant Head and Neck Cancer Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil PD-1 Resistant Head and Neck Cancer Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By End User
    • 10.3.2. Colombia PD-1 Resistant Head and Neck Cancer Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By End User
    • 10.3.3. Argentina PD-1 Resistant Head and Neck Cancer Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global PD-1 Resistant Head and Neck Cancer Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Ayala Pharmaceuticals D srl.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Amgen Inc.
  • 15.3. AstraZeneca plc.
  • 15.4. Boehringer Ingelheim International GmbH
  • 15.5. Bristol-Myers Squibb Company
  • 15.6. Cel-Sci
  • 15.7. GSK plc
  • 15.8. Incyte
  • 15.9. Merck KGaA
  • 15.10. Novartis AG

16. Strategic Recommendations

17. About Us & Disclaimer